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Introduction: The German Lung Cancer Screening Intervention Trial 
(LUSI) is one of the European randomized trials investigating the 
efficacy of low-dose multislice computed tomography (MSCT) as a 
screening tool for lung cancer. In the evaluation of the first (preva-
lence) screening round, we observed exceptionally high early recall 
rates, which made the routine application of MSCT screening ques-
tionable. Because screening may behave differently in subsequent 
(incidence) screening rounds, we analyzed (a) basic characteristics for 
the annual rounds 2 to 4, which have now also been completed, and (b) 
the first 3 years with complete follow-up since time of randomization.
Methods: Data material was the data record of LUSI after the fourth 
screening round and the 3-year follow-up had been completed. Basic 
characteristics of screening, e.g., early recall rate, detection rate, and 
interval cancers as well of proportion of advanced cancers, were 
descriptively evaluated and, if informative, group differences were 
tested for statistical significance.
Results: Early recall rates were significantly lower in the subsequent 
screening rounds than in the first one if the MSCT information from 
the previous screening rounds was available. Detection and biopsy 
rates were approximately 1% or lower, ratio of benign:malignant 
biopsies: 1:1.6 to 1:3.
Conclusion: Our recent data may not only settle one concern regarding 
high recall rates in routine MSCT screening but also indicate that screen-
ing must be strictly organized to be effective. Performance indicators are 
similar to those in mammography screening. Nevertheless, possible con-
sequences for the participants (diagnostic workup of suspicious findings, 
biopsies) are more invasive than in mammography screening.
Key Words: cancer, low-dose CT, lung, randomized trial, screening.
(J Thorac Oncol. 2015;10: 890–896)
Several randomized trials investigating the effectiveness of lung cancer screening with multislice computed tomogra-
phy (MSCT) are under way in the United States1 and Europe 
(reviewed in Refs. 2–8) from which the American National 
Lung Screening Trial having provided first results.
One of the European trials is the German Lung Cancer 
Screening Intervention Trial (LUSI), which started in 2007 
with 4052 study participants. One key result of its first screen-
ing round was the high early recall rate of approximately 20% 
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early recalls because of suspicious MSCT findings. Most of 
these were false-positive, which would make MSCT screen-
ing questionable for a routine program.9 However, because 
screening may behave rather differently in the first (preva-
lence) screening round and subsequent (incidence) rounds, 
we analyzed the data of the subsequent rounds of LUSI with 
particular attention to the basic performance indicators of 
screening, such as early recall rate, detection rate, and interval 
cancer rate.
Because all participants have gone through at least 3 years 
of observation since randomization and many participants have 
gone through even 5 years or more of observation at the time 
of this evaluation, further indicators of the progress of this trial, 
such as false-positive and detection rates, interval cancers (inva-
sive cancers diagnosed in an attender after a negative screen and 
before the next invitation to screening was due10), development 
of cumulative advanced incidence, or overall mortality in the 
study arms, can now be presented descriptively. They are par-
tially indicative for the quality of the trial itself (advanced cancer 
incidence and overall mortality shortly after randomization) and 
partially early surrogates for the later mortality outcome of the 
trial (cumulative advanced cancer incidence rate).
MATERIAL AND METHODS
Data Material
The German LUSI trial is an epidemiological study 
among 50–69 years old males and females with a history of 
heavy smoking (at least 25 years smoking of at least 15 ciga-
rettes per day or at least 30 years smoking of at least 10 ciga-
rettes per day) randomized into a screening intervention arm, 
comprising a MSCT at time of randomization and four subse-
quent annual MSCTs, and a control arm with no intervention. 
Recruitment was population based from a random sample of 
the population registers in the area around Heidelberg yield-
ing 4052 participants (2029 screenees and 2023 controls). 
Follow-up is being conducted actively by annual questionnaire 
mailing and passively by repeated linkage to the local popu-
lation registers and cancer registries. Randomization started 
at October 23, 2007 and ended at April 11, 2011. A detailed 
description of study design was given by Becker et al.9
In the present evaluation, the data describing the status of 
the trial at April 30, 2014 were used, comprising the first four 
completed screening rounds. Partially, we refer to data from 
the fifth round, which has also been completed for about two-
third of the participants by this time. For evaluations in terms 
of events (e.g., lung cancer diagnosis, death) by time since ran-
domization, complete follow-up data are available for at least 3 
years since randomization (for those who were randomized in 
April 2011) and up to 6.5 years (for those who were random-
ized in October 2007). The data on incident lung cancers were 
obtained for the screening group from the annual MSCT scans, 
and in the control group from the annual questionnaire inqui-
ries followed by data collection from the treating physicians 
in case of self-reported lung cancer diagnoses. In addition, a 
linkage with the local cancer registry of Baden-Württemberg 
and the local population registries was carried out. Partially, we 
also describe also the already available data on incident lung 
cancers or deaths from any cause for those years (3–6.5 years 
of observation) for which follow-up is still incomplete.
MSCT Evaluation Algorithm
All MSCT datasets were subject to a dedicated post-pro-
cessing server for computer-aided detection and nodule volum-
etry (Median Software, France). A key issue of the evaluation 
algorithm is the distinction between newly observed and pre-
viously identified nodules (Table 1). MSCTs with no nodules 
or nodules below 5 mm in diameter were considered negative 
implying continuation of routine screening after 12 months.
Newly observed nodules (Table 1, left column): All other 
newly observed nodules were classified as suspicious implying 
early recall depending on size of the largest observed nodule: 
Reinvitation with repeat MSCT after 6 months (largest nodule 
5–7 mm in diameter), 3 months (8–10 mm), or immediate pul-
monologist referral for workup (larger than 10 mm, respectively).
Known nodules (Table 1, right column): Nodules known 
from the previous screening round or especially the repeat 
MSCTs of the early recalls were first checked whether they 
TABLE 1.  MSCT Evaluation Algorithm Applied in the German Randomized Lung Cancer Screening Trial LUSI
Newly Observed Nodules (First Screening Round or  
New in Subsequent Rounds)
Known Nodules (Early Recalls or  
Subsequent Screening Rounds)
Outcome by Nodule Size Action Outcome by Nodule Growth Action
Without abnormality or  
nodules <5 mm
Back to routine screening  
(12 months)
Nodules 5–7 mm Early recall (6 months) >600 VDT Back to routine screening
400–600 VDT
 < 7.5 mm Early recall (6 months)
 ≥ 7.5–10 mm Early recall (3 months)
≤400 VDT or > 10 mm Immediate recall
Nonmalignant Back to routine screening
Nodules 8–10 mm Early recall (3 months) Malignant Treatment
Nodules >10 mm/not highly suspicious Early recall (3 months)
Highly suspicious Immediate recall
MSCT, multislice computed tomography; LUSI, lung cancer screening intervention trail; VDT, volume doubling time.
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were still present. If still existent, their volume doubling time 
(VDT) was calculated. Disappearance of nodules or a VDT 
above 600 days was considered negative and reported accord-
ingly to the participants who were then scheduled for the next 
routine screening after 12 months.
VDT between 400 and 600 days lead to an early recall 
after another 6 or 3 months according to whether the nodule 
had a diameter of less than 7.5 mm or 7.5 to 10 mm, and VDT 
under 400 days and all nodules more than 10 mm in diameter 
were immediately recalled.
In case of immediate recall, the participant was recom-
mended to consult an office-based pulmonologist. All further 
measures taken were at his or hers discretion and could imply 
antibiotic treatment and computed tomography control after 
several weeks, positron emission tomography imaging, or 
immediate biopsy.
Histology
The lung cancers were coded according to ICD-O-3. For 
this article, the morphology codes were combined to the fol-
lowing groups: (a) small-cell lung cancers (ICD-O-3: 8041-3, 
8044-3, 8045-3); (b) non–small-cell lung cancers, subdivided 
into squamous cell carcinoma (8071-3, 8072-3, 8078-3, 8083-
3), adenocarcinoma (8140-2, 8140-3, 8250-3, 8252-3, 8255-3, 
8260-3, 8310-3, 8480-3, 8490-3, 8550-3, 8574-3), and large 
cell carcinoma (8013-3); (c) carcinoids (8240-3); and (d) car-
cinoma unspecified (8010-3).
Statistical Methods
Most data were presented descriptively in form of 
absolute figures with percentages, proportions including 
95% confidence limits or rates, respectively. Tests on dif-
ferences of proportions were carried out with Fishers’s 
exact test (histology, cumulative advanced lung cancers, 
and cumulative overall mortality11). Trends in the rate of 
advanced lung cancers were tested with the Jonckheere 
trend test. All evaluations were computed with SAS (SAS 
Institute, Inc, Cary, NC).
RESULTS
Compliance to Screening Rounds 2 to 4
For all three considered screening rounds, more than 
90% invited screenees did attend (Table 2). From the 2028 
screenees of screening round 1, 2000 were invited to round 
2 and 1892 attended (94.6%). Twenty-eight participants had 
not been invited because of lung cancer (n = 23) or death 
(n = 5). Some participants obmitted the current MSCT screen-
ing round (but attended the next one), but sent back a filled-in 
questionnaire. Some failed to send back the questionnaire, but 
were still in follow-up (n = 109). Up to April 2014, one of the 
MSCT screenees was lost to follow-up. Because of this high 
compliance, more than 60% of the screenees completed already 
five screening rounds and approximately 25% four rounds. 
Thus, almost 90% of the screenees have had at least four MSCT 
scans (data not shown in table). The compliance in the control 
group regarding filling in the annual questionnaires was simi-
larly high with five participants being lost to follow-up.
Performance Indicators
The number of early recalls dropped significantly 
from almost 400 screenees (nearly 20%) in the first round9 to 
approximately 50 to 70 (~3–4%) in the screening rounds 2 to 4 
(p < 0.0001, Table 3). The rate of immediate recalls remained 
rather stable and ranged between 1.4% (screening round 3) and 
2.9% (screening round 5). Overall, only 24 participants who 
had an early recall would receive another one as consequence 
of this first recall. This may be important in view of the overall 
radiation exposure. The detection rate dropped from 1.1% in 
the first round to 0.5% to 0.6% in rounds 2 to 4. Four interval 
cancers occurred so far, one after screening round 1, two after 
screening round, 3 and one after screening round 4 resulting in a 
proportion of 6.5% interval cancers in the screening group. On 
the basis of the current case numbers, the lung cancer incidence 
rate was approximately 363 cases per 100,000 person-years 
in the control arm and approximately 674 cases per 100,000 
person-years in the MSCT arm (data not shown in table).
TABLE 2.  Status of the Study Arms by End of Screening Round 4
Screening  
Round
Screening Arm Control Arm
n = 2029 n = 2023
Invited to MSCT/ 
Attended MSCT (%)
Not Invited: LCa/ 
Deceased
Not Attended but in 
Follow-up/Lost to 
Follow-up (No Contact 
or Withdrawal)
Questionnaire Sent 
out/Questionnaire 
Returned
Not Contacted: 
Deceased
Not Compliant 
but in Follow-up/ 
Lost to Follow-up 
(No Contact or 
Withdrawal)
1 2029c/2028d (99.9%) – 1/0 2023/2022 (99.9%) – 0/1
2 2000/1892 (94.6%) 23/5 109/0 2018/1847 (91.5%) 4 171/1
3 1978/1849 (93.4%) 34/15 131/0 2005/1897 (94.5%) 16 108/2
4 1958/1826 (93.1%) 43/25 134/1 1988/1898 (95.5%) 30 90/5
5b 1656/1565 (94.5%) 51/38 119/3 1599/1515 (94.7%) 43 84/7
aLung cancer cases are not invited to screening but obtain a follow-up questionnaire, similar to controls, with additional questions on quality of life.
bThe last screening round is still running (data from September 2014; finalization: April 2015).
cOne subject was excluded because his weight exceeded the permitted maximum weight of the MSCT device.
dOne subject provided noisy unevaluable MSCTs in screening rounds 1 and 2 and was not invited later on.
MSCT, multislice computed tomography.
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Nodule Evaluation only by Size
Because the early recall rate is crucial for the acceptabil-
ity of a screening program and differed so strongly between 
first and subsequent screening rounds, we investigated the 
effect of an alternative “naive” evaluation of the subsequent 
screening rounds only by nodule size as determined by the 
radiologists, but without taking prior images into account, 
as it were, e.g., the case if a screenee changed the doctor for 
every MSCT scan. Table 4 shows that the number of screenees 
with nodules being suspicious because of their size remained 
constantly in the order of 500 or more. Had prior scans been 
unavailable, this would again have lead to early recall rates of 
almost 30%, as high as in the first screening round.
Histology of Lung Cancers
From the 62 lung cancers observed by September 5, 2014 
in the MSCT arm (58 screen-detected, four interval cancers), 
3 were small-cell carcinomas, 56 non-small cell carcinomas 
(NSCLC), 2 carcinoids and one carcinoma unspecified. The 
NSCLC comprised 10 squamous cell carcinomas, 45 adenocar-
cinomas, and 1 large-cell carcinoma (Fig. 1). The corresponding 
numbers for the 32 lung cancers in the control arm were 9 small-
cell carcinoma, 6 squamous-cell carcinoma, 16 adenocarcinoma, 
and 1 large-cell carcinoma. The difference of the observed pat-
terns was statistically highly significant (p < 0.0001).
Advanced Lung Cancers
Among the screen-detected lung cancers, 16 were in 
UICC stage II or above (Table 3). Expressed as proportions 
among all screen-detected lung cancers, these were 26.1%, 
45.5%, 22.2%, 12.5%, and 28.6% in the five screening rounds, 
respectively (p
Trend
 = 0.077, data not shown in table). Including 
the interval cancers, and evaluating according to years after 
randomization, 18 of the lung cancers in the MSCT group were 
in UICC stage II+ (by year after randomization: 5, 7, 3, 2, and 
1, respectively), whereas we observed 29 in the control group 
(4, 7, 8, 7, and 3, respectively). The rate of advanced cancers 
dropped in the MSCT group from 0.25% to 0.35% of the 
TABLE 4.  Hypothetical Screening Outcome if Only Nodule Sizes Were Taken into Account Based on the Observed Nodule 
Sizes in the Annual MSCT Screening Rounds of LUSI
Characteristic
Observed Screening Outcome by Nodule Size
Round 1 Round 2 Round 3 Round 4 Round 5a
Total number of participants 2028 1892 1849 1826 1565
Without abnormality or nodule 5 mm 
or less
1488 1343 1320 1269 1067
Suspicious nodule (s) implying early 
recall by nodule size
540 549 529 557 498
5–7 mm 393 406 361 357 335
8–10 mm 78 71 92 105 89
10 mm or more 69 72 76 95 74
Hypothetical proportion of early recalls 
among all participants in % (95% CL)
26.6 (24.7, 
28.6)
29.0 (27.0, 31.1) 28.6 (26.6, 30.7) 30.5 (28.4, 32.7) 31.8 (29.5, 34.2)
aIncomplete screening round.
MSCT, multislice computed tomography; LUSI, lung cancer screening intervention trail; CL, confidence limits.
TABLE 3.  Performance Indicators for the Screening Rounds 1 to 5 in the German Lung Cancer Screening Trial LUSI
Screening 
Round
Number of 
Screenees
Early Recalls (3 and 6 months/ 
Immediate); % (95% CL)
Second Recalls 
After a First Early 
Recall; Number, 
% of Recalls
Biopsies Number of 
Benign/Malignant 
Biopsies, Ratio, 
Proportion of 
Participants
Lung Cancers Number; 
UICC Stages: IA, IB, 
IIA, IIB, IIIA, IIIB, IV; 
Detection Rate in % 
(95% CL)
Interval Cancers 
Number Rate (%), 
UICC Stage
1a 2028 n = 451 (398/53); 22.2% (20.5, 24.1) 10/23, 1:2.3, 1.6% n = 23; 10, 7, 1, 1, 3, 0, 1, 
1.1% (0.7, 1.7)
n = 1 (0.05%), IV
2 1892 n = 88 (52/36); 4.7% (3.8, 5.7) n = 2, 3.8% 4/11, 1:2.8, 0.8% n = 11; 5, 1, 0, 1, 1, 1, 2, 
0.6% (0.3, 1.0)
n = 0
3 1849 n = 74 (49/25); 4.0% (3.2, 5.0) n = 5, 10.2% 3/9, 1:3, 0.6% n = 9; 6, 1, 1, 0, 1, 0, 0, 
0.5% (0.2, 0.9)
n = 2 (0.11%), IA, 
IV
4 1826 n = 103 (70/33); 5.7% (4.7, 6.9) n = 10, 14.3% 5/8, 1:1.6, 0.7% n = 8; 6, 1, 0, 1, 0, 0, 0, 
0.4% (0.2, 0.9)
n = 1b (0.057%), IIIA
5b 1565 n = 89 (63/26); 5.7% (4.6, 7.0) n = 10, 15.9% 1/7, 1:7, 0.5% n = 7; 5, 0, 1, 0, 1, 0, 0, 
0.4% (0.2, 1.0)
n = 0b
aThe first publication by Becker et al.9 reported a higher early recall rate of 26.6%. With this higher number, the rate of suspicious findings was provided, but because of expert 
opinion of the radiologists, some of these findings did not lead to an early recall. The rate presented here refers to the truly executed early recall invitations.
bScreening round not yet completed. The data describe the status of the round by September 2014.
LUSI, lung cancer screening intervention trail.
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invited screenees in the first two rounds to 0.06% in the fifth 
(incomplete) screening round (p
Trend
 = 0.050, Fig. 2). In the 
control group, the rate of advanced cancers fluctuated within 
a range of 0.2% to 0.4% without any trend (p
Trend
 = 0.6242). 
The cumulative number of advanced lung cancers was almost 
identical in the two study arms for the first 2 years after ran-
domization, but seemed to diverge from the third year onward 
(Fig. 3) without statistical significance, however p = 0.2494.
Overall Mortality by Time Since Randomization
Figure 4 shows that cumulative overall mortality, i.e., 
mortality from any cause, was almost identical for the two study 
arms in the first 2 years after randomization (MSCT group: 5 
and 9 cases, control group: 4 and 12 cases) and might diverge 
slightly from the third year onward (MSCT: 11, 11, and 7 cases, 
controls: 15, 12, and 11 cases, respectively; p = 0.2601).
DISCUSSION
A key result of this evaluation was the strong decline 
of the early recall rate in the screening rounds 2 to 4. The 
detection rate leveled off to about the half of that of the first 
screening round, whereas the proportion of advanced lung 
cancers remained high at first and decreased only from screen-
ing round 3 onward. The cumulative number of advanced lung 
cancers and deaths from any cause were well balanced in 
the two study arms for the first 2 years after randomization. 
Diverging numbers of advanced lung cancers from screening 
FIGURE 1.  Proportional distribution of the histological 
diagnoses of the lung cancer cases detected until September 
5, 2014 in the multislice computed tomography arm and the 
control arm of lung cancer screening intervention trial.
FIGURE 2.  Rates of advanced lung cancers (UICC stage II and 
above) by time since randomization and trial arm in percent.
FIGURE 3.  Cumulative number of advanced lung cancers 
in the multislice computed tomography-screening arm and 
control arm of lung cancer screening intervention trial in 
dependence on observation time since randomization. The 
dotted lines are based on the preliminary data of observa-
tional periods with still uncompleted follow-up.
FIGURE 4.  Cumulative number of deaths from any cause 
in the multislice computed tomography-screening arm and 
control arm of lung cancer screening intervention trial in 
dependence on observation time since randomization. The 
dotted lines are based on the preliminary data of observa-
tional periods with still uncompleted follow-up.
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round 3 onward might indicate that future lung cancer mortal-
ity might level off in the screening arm compared with the 
control arm.
Early Recall Rate
In screening, early recalls most frequently result from 
false-positive findings and are thus undesired side effects of the 
intervention. For comparison, in mammography screening, a 
low proportion of participants with a false-positive screening 
result is a quality indicator for the program, and the European 
Guidelines recommend a target of less than 5% in the first and 
less than 4% in the subsequent screening rounds. The rate of 
false-positive findings of approximately 18% (19.6% early 
recalls minus 1.1% detection rate of true lung cancers) in the 
first screening round of our lung cancer study was clearly above 
this level and makes routine lung cancer screening with MSCT 
questionable. To make matters even worse, suspicious find-
ings at lung cancer screening with MSCT cannot be worked up 
as immediately and noninvasively as those at mammography 
screening. Other than with unambiguous and more advanced 
cancer, and given the risks of open or thoracoscopic lung biopsy, 
many patients with unclear findings will first undergo attempts 
at conservative treatment and control scans for possible inflam-
matory lesions, consultations, etc., before eventually a biopsy is 
performed. This may need time, with all psychological impli-
cations. Patients with smaller nodules, although having been 
informed that the nodule is rather unlikely to be malignant, will 
have to spend another 3 or 6 months in uncertainty.
We found that the proportion of early recalls declined 
substantially in the incidence screening rounds. As a result, 
this crucial parameter now lies at a level comparable to that in 
mammography screening, but, again, only as a result of com-
paring nodule diameters to those in previous rounds. It follows 
that for lung cancer screening, previous images must be held 
available for comparison.
Our initially high proportion of positive findings/early 
recalls (22.2%) corresponds with reported data from NLST12 
(27.9%) and the other European studies8 (15.2–30.2%) for 
the first round. For the second round, the recall rate of LUSI 
(4.7%) appears lower than that in the NLST13 (16.8%) but 
comparable with the one reported from the other European 
studies8 (3.8–17.0%).
Detection Rates, Biopsies, and Interval Cancers
The detection rates, 1.1% in the initial and about half 
of that in later screening rounds, are comparable with those in 
the other trials (see Ref. 8: initially 0.8–2.2%; second round, 
0.4–0.6%) and also to those in mammography screening (see, 
e.g., Ref. 14: 0.4–1.1% and 0.3–0.4%). Similar findings are 
also for the proportion of benign biopsies in screening attend-
ees (approximately 0.3% in our lung screening trial; for mam-
mography screening14: 0.1–0.8%; most programs 0.3–0.4%) 
and the ratio of benign to malignant biopsy results (1:2.6 in 
this trial; for mammography screening15: 1:1.6 to 1:4).
Proportion of Advanced Lung Cancers
In the European Guidelines for mammography screen-
ing (2002), a proportional decrease of advanced breast cancers 
from 25% in the first screening round to 20% in the subsequent 
rounds is recommended. In our lung cancer trial, a leveling off 
of advanced cancers (in terms of both rates and proportions) 
seemed to occur only in the third or fourth screening round 
and then seemed to approach a range comparable with that 
of mammography screening, but not yet in the second round. 
These findings may not yet be statistically significant, but they 
are worth reporting because they fit into the observation of 
the radiologists that most of the round 2 cancers were vis-
ible already in the first round. At the earlier instance, they had 
been classified as “not suspicious,” because they did not meet 
the size criteria for immediate recall and were subsequently 
only captured because of their growth until the second round. 
Again, this emphasizes the need for previous image records 
held available in a screening program.
The proportion of advanced lung cancers should in any 
case be examined on a larger scale with pooled data. In other 
studies for which screening round-related data were pub-
lished, the NLST also showed high proportions of advanced 
cancers, which did not drop immediately after the prevalence 
round.12,13 So did the Danish DLCST,2 but not the MILD trial16 
(n = 0 advanced lung cancers in round 2) or the NELSON 
trial6 (35.1% for screening round 1 and 25.1% for round 2).
Strengths of the Study
Strengths of our study are the high compliance of the 
participants in both study arms with almost no loss to follow-
up and the apparently well-effectuated randomization: a first 
screening round is unable to affect the course of those can-
cers, which at the time of screening already are in an advanced 
stage. Thus, advanced cancers should be well balanced in the 
screening arm and the control arm in the first year after start of 
the study just as it was the case in LUSI. Correspondingly, the 
first screening round is unable to affect overall mortality in the 
first few years after randomization so that this was also almost 
identical at first in the both study arms of our trial. On the 
long term, if effective, screening should help to early resect 
those cancers, which would otherwise become advanced. This 
is just what in tendency, i.e., far away from statistical con-
firmation, can be observed in Figure 4 where advanced lung 
cancers seem to become less frequent in the MSCT than in 
the control arm from year 3 onward. We did not evaluate lung 
cancer mortality for methodological reasons because interim 
evaluations were not part of the study design.
Limitations
Limitations of the study are the small size of 4052 par-
ticipants overall and the late start of recruitment in 2007. 
Both were due to limited resources and a difficult search 
for grant support. All European studies mentioned in the 
introduction section are limited in size and will have to be 
evaluated in common to achieve together a reasonable power. 
Therefore, good data quality from all studies might be as 
crucial as the size.
Conclusion
For a screening program to be acceptable, its undesired 
side effects must be limited to a reasonable minimum. Our 
Copyright © 2014 by the International Association for the Study of Lung Cancer
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data indicate that the most prominent side effect “false-pos-
itive alarm” cannot be controlled if the choice of doctor is 
at the screenee’s discretion at every annual screening visit. 
Rather, a potential lung screening program must be so orga-
nized that all previous images and results are available. With 
the exception of the first screening round, the false-positive 
rate and many other parameters important in screening will 
be then in a range, which is comparable with what is seen in 
breast cancer screening with mammography.
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